University of Hertfordshire

From the same journal

By the same authors

Standard

Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice. / Geisler, Tobias; Jorbenadze, Rezo; Popov, Aron-Frederik; Mueller, Karin L.; Rath, Dominik; Droppa, Michal ; Schreieck, Juergen ; Seizer, Peter; Storey, Robert F.; Kristensen, Steen D.; Rubboli, Andrea; Gorog, Diana; Aradi, Daniel; Sibbing, Dirk; Huber, Kurt; Gawaz, Meinrad; Berg, Jur Ten.

In: Thrombosis and haemostasis, Vol. 19, No. 10, 17.08.2019, p. 1590-1605.

Research output: Contribution to journalArticlepeer-review

Harvard

Geisler, T, Jorbenadze, R, Popov, A-F, Mueller, KL, Rath, D, Droppa, M, Schreieck, J, Seizer, P, Storey, RF, Kristensen, SD, Rubboli, A, Gorog, D, Aradi, D, Sibbing, D, Huber, K, Gawaz, M & Berg, JT 2019, 'Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice', Thrombosis and haemostasis, vol. 19, no. 10, pp. 1590-1605. https://doi.org/10.1055/s-0039-1694751

APA

Geisler, T., Jorbenadze, R., Popov, A-F., Mueller, K. L., Rath, D., Droppa, M., Schreieck, J., Seizer, P., Storey, R. F., Kristensen, S. D., Rubboli, A., Gorog, D., Aradi, D., Sibbing, D., Huber, K., Gawaz, M., & Berg, J. T. (2019). Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice. Thrombosis and haemostasis, 19(10), 1590-1605. https://doi.org/10.1055/s-0039-1694751

Vancouver

Author

Geisler, Tobias ; Jorbenadze, Rezo ; Popov, Aron-Frederik ; Mueller, Karin L. ; Rath, Dominik ; Droppa, Michal ; Schreieck, Juergen ; Seizer, Peter ; Storey, Robert F. ; Kristensen, Steen D. ; Rubboli, Andrea ; Gorog, Diana ; Aradi, Daniel ; Sibbing, Dirk ; Huber, Kurt ; Gawaz, Meinrad ; Berg, Jur Ten. / Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice. In: Thrombosis and haemostasis. 2019 ; Vol. 19, No. 10. pp. 1590-1605.

Bibtex

@article{1a9b9e772c59434d86d6b547da6a97da,
title = "Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice",
abstract = "As the number of, and the indications for, structural heart interventions are increasing worldwide, the optimal secondary prevention to reduce device thrombosis is becoming more important. To date, most of the recommendations are empiric. The current review discusses mechanisms behind device-related thrombosis, the available evidence with regard to antithrombotic regimen after cardiac device implantation, as well as providing an algorithm for identification of risk factors for device thrombogenicity and for management of device thrombosis after implantation of patent foramen ovale and left atrial appendage occluders, MitraClips/transcatheter mitral valve replacement, pacemaker leads, and left ventricular assist devices. Of note, the topic of antithrombotic therapy and thrombogenicity of prostheses in aortic position (transcatheter aortic valve replacement, surgical, mechanical, and bioprostheses) is not part of the present article and is discussed in detail in other contemporary focused articles.",
keywords = "MitraClip, device-related thrombosis, left atrial appendage, left ventricular assist device, patent foramen ovale",
author = "Tobias Geisler and Rezo Jorbenadze and Aron-Frederik Popov and Mueller, {Karin L.} and Dominik Rath and Michal Droppa and Juergen Schreieck and Peter Seizer and Storey, {Robert F.} and Kristensen, {Steen D.} and Andrea Rubboli and Diana Gorog and Daniel Aradi and Dirk Sibbing and Kurt Huber and Meinrad Gawaz and Berg, {Jur Ten}",
year = "2019",
month = aug,
day = "17",
doi = "10.1055/s-0039-1694751",
language = "English",
volume = "19",
pages = "1590--1605",
journal = "Thrombosis and haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "10",

}

RIS

TY - JOUR

T1 - Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice

AU - Geisler, Tobias

AU - Jorbenadze, Rezo

AU - Popov, Aron-Frederik

AU - Mueller, Karin L.

AU - Rath, Dominik

AU - Droppa, Michal

AU - Schreieck, Juergen

AU - Seizer, Peter

AU - Storey, Robert F.

AU - Kristensen, Steen D.

AU - Rubboli, Andrea

AU - Gorog, Diana

AU - Aradi, Daniel

AU - Sibbing, Dirk

AU - Huber, Kurt

AU - Gawaz, Meinrad

AU - Berg, Jur Ten

PY - 2019/8/17

Y1 - 2019/8/17

N2 - As the number of, and the indications for, structural heart interventions are increasing worldwide, the optimal secondary prevention to reduce device thrombosis is becoming more important. To date, most of the recommendations are empiric. The current review discusses mechanisms behind device-related thrombosis, the available evidence with regard to antithrombotic regimen after cardiac device implantation, as well as providing an algorithm for identification of risk factors for device thrombogenicity and for management of device thrombosis after implantation of patent foramen ovale and left atrial appendage occluders, MitraClips/transcatheter mitral valve replacement, pacemaker leads, and left ventricular assist devices. Of note, the topic of antithrombotic therapy and thrombogenicity of prostheses in aortic position (transcatheter aortic valve replacement, surgical, mechanical, and bioprostheses) is not part of the present article and is discussed in detail in other contemporary focused articles.

AB - As the number of, and the indications for, structural heart interventions are increasing worldwide, the optimal secondary prevention to reduce device thrombosis is becoming more important. To date, most of the recommendations are empiric. The current review discusses mechanisms behind device-related thrombosis, the available evidence with regard to antithrombotic regimen after cardiac device implantation, as well as providing an algorithm for identification of risk factors for device thrombogenicity and for management of device thrombosis after implantation of patent foramen ovale and left atrial appendage occluders, MitraClips/transcatheter mitral valve replacement, pacemaker leads, and left ventricular assist devices. Of note, the topic of antithrombotic therapy and thrombogenicity of prostheses in aortic position (transcatheter aortic valve replacement, surgical, mechanical, and bioprostheses) is not part of the present article and is discussed in detail in other contemporary focused articles.

KW - MitraClip

KW - device-related thrombosis

KW - left atrial appendage

KW - left ventricular assist device

KW - patent foramen ovale

UR - http://www.scopus.com/inward/record.url?scp=85072746522&partnerID=8YFLogxK

U2 - 10.1055/s-0039-1694751

DO - 10.1055/s-0039-1694751

M3 - Article

VL - 19

SP - 1590

EP - 1605

JO - Thrombosis and haemostasis

JF - Thrombosis and haemostasis

SN - 0340-6245

IS - 10

ER -